Blockchain Registration Transaction Record

Molecular Precision Targets Blind Spot in Heart Disease Detection

Cardio Diagnostics Holdings (CDIO) addresses a blind spot in coronary heart disease detection with epigenetic and genetic tests, improving sensitivity over traditional risk calculators.

Molecular Precision Targets Blind Spot in Heart Disease Detection

This news matters because coronary heart disease is the leading cause of death in the US, yet current diagnostic tools miss half of cases. Cardio Diagnostics' epigenetic and genetic tests could revolutionize early detection, potentially saving lives by identifying at-risk individuals who are currently overlooked. For patients and healthcare providers, this means a more accurate, personalized approach to preventing heart attacks.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0xe7e5118594bf7a7048b4366dde2c3049eaed2a2a7ec88c9c797e42244d6bc011
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintyarnFKPi-7ee3df6a72f272bc72e2f06c8568162b